Karyopharm Therapeutics Inc. (KPTI)

Price$8.94

Favorite Metrics

Price vs S&P 500 (26W)47.80%

Price vs S&P 500 (4W)3.35%

Market Capitalization$193.06M

All Metrics

Book Value / Share (Quarterly)$0.68

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.40%

Cash Flow / Share (Quarterly)$-4.12

Price vs S&P 500 (YTD)12.85%

Gross Margin (TTM)95.93%

Net Profit Margin (TTM)-134.21%

EPS (TTM)$-16.60

10-Day Avg Trading Volume0.60M

EPS Excl Extra (TTM)$-16.60

Revenue Growth (5Y)6.21%

EPS (Annual)$-17.93

ROI (Annual)-81.28%

Gross Margin (Annual)95.93%

Net Profit Margin (5Y Avg)-89.84%

Cash / Share (Quarterly)$3.48

Revenue Growth QoQ (YoY)11.58%

ROA (Last FY)-180.82%

Revenue Growth TTM (YoY)0.57%

EBITD / Share (TTM)$-13.96

ROE (5Y Avg)-210.81%

Operating Margin (TTM)-104.80%

Cash Flow / Share (Annual)$-4.12

P/B Ratio3.82x

P/B Ratio (Quarterly)22.52x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)2.96x

Net Interest Coverage (TTM)-3.55x

ROA (TTM)-179.34%

EPS Incl Extra (Annual)$-17.93

Current Ratio (Annual)1.12x

Quick Ratio (Quarterly)0.98x

3-Month Avg Trading Volume0.80M

52-Week Price Return94.80%

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$-0.88

P/S Ratio (Annual)1.32x

Asset Turnover (Annual)1.35x

52-Week High$10.99

Operating Margin (5Y Avg)-76.47%

EPS Excl Extra (Annual)$-17.93

CapEx CAGR (5Y)-7.53%

26-Week Price Return56.55%

Quick Ratio (Annual)0.98x

13-Week Price Return19.75%

Total Debt / Equity (Annual)3.78x

Current Ratio (Quarterly)1.12x

Enterprise Value$431.754

Revenue / Share Growth (5Y)54.83%

Asset Turnover (TTM)1.34x

Book Value / Share Growth (5Y)-34.14%

Revenue / Employee (Annual)$1

Inventory Turnover (Annual)1.36x

Pretax Margin (Annual)-134.18%

Cash / Share (Annual)$3.48

3-Month Return Std Dev100.94%

Gross Margin (5Y Avg)96.70%

Net Income / Employee (TTM)$-1

ROE (Last FY)-388.71%

Net Interest Coverage (Annual)-3.55x

EPS Basic Excl Extra (Annual)$-17.93

Receivables Turnover (TTM)5.13x

Total Debt / Equity (Quarterly)3.78x

EPS Incl Extra (TTM)$-16.60

Receivables Turnover (Annual)5.13x

ROI (TTM)-66.32%

P/S Ratio (TTM)1.32x

Pretax Margin (5Y Avg)-89.70%

Revenue / Share (Annual)$13.36

Tangible BV / Share (Annual)$-0.15

Price vs S&P 500 (52W)59.70%

Year-to-Date Return16.98%

5-Day Price Return3.99%

EPS Normalized (Annual)$-17.93

ROA (5Y Avg)-74.72%

Net Profit Margin (Annual)-134.21%

Month-to-Date Return54.58%

Cash Flow / Share (TTM)$-1.29

EBITD / Share (Annual)$-13.96

Operating Margin (Annual)-104.80%

LT Debt / Equity (Annual)3.78x

ROI (5Y Avg)-79.29%

LT Debt / Equity (Quarterly)3.78x

EPS Basic Excl Extra (TTM)$-16.60

P/B Ratio (Annual)22.52x

Inventory Turnover (TTM)1.36x

Pretax Margin (TTM)-134.18%

Book Value / Share (Annual)$0.68

Price vs S&P 500 (13W)16.88%

Beta0.80x

Revenue / Share (TTM)$8.12

ROE (TTM)-182.43%

52-Week Low$3.65

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.17

4.15

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
KPTIKaryopharm Therapeutics Inc.	1.32x	0.57%	95.93%	—	$8.94
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Karyopharm Therapeutics is a commercial-stage pharmaceutical company specializing in cancer drugs that inhibit nuclear export. The company's lead product, XPOVIO (selinexor), targets exportin 1 (XPO1), preventing the transport of cancer-promoting proteins out of the cell nucleus. This mechanism represents a novel approach to disrupting cancer cell survival.